Integra Lifesciences Holdings (IART) Amortization of Deferred Charges (2009 - 2022)

Integra Lifesciences Holdings (IART) has 14 years of Amortization of Deferred Charges data on file, last reported at $1.6 million in Q3 2022.

• For the quarter ending Q3 2022, Amortization of Deferred Charges rose 188.44% year-over-year to $1.6 million; the trailing twelve-month figure through Sep 2022 stood at $3.6 million (up 2.85% YoY), and the FY2019 full-year result was $5.4 million, down 14.04% from the prior year.
• Amortization of Deferred Charges improved to $1.6 million in Q3 2022, from $1.4 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $2.1 million in Q2 2018 to a low of -$17000.0 in Q1 2022.
• A 5-year average of $1.2 million and a median of $1.4 million in 2019 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges jumped 755.06% in 2021 and plunged 101.12% in 2022, its largest moves.
• Tracing IART's Amortization of Deferred Charges over 5 years: stood at $1.3 million in 2018, then soared by 45.56% to $1.9 million in 2019, then slumped by 78.51% to $412000.0 in 2020, then soared by 38.59% to $571000.0 in 2021, then surged by 188.44% to $1.6 million in 2022.
• Business Quant data shows IART's Amortization of Deferred Charges at $1.6 million in Q3 2022, $1.4 million in Q2 2022, and -$17000.0 in Q1 2022.